<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615181</url>
  </required_header>
  <id_info>
    <org_study_id>00009</org_study_id>
    <nct_id>NCT05615181</nct_id>
  </id_info>
  <brief_title>Evaluation of the French Translation of Gothenburg Trismus Questionnaire (GTQ)</brief_title>
  <acronym>TRISMUS</acronym>
  <official_title>Evaluation of the French Translation of Gothenburg Trismus Questionnaire (GTQ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier de Valence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gothenburg University, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier de Valence</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A monocentric Study to evaluate the french translation of Gothenburg Trismus Questionnaire&#xD;
      (GTQ).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trismus is defined as a limitation in the mouth/jaw-opening ability due to a reduced mandible&#xD;
      mobility. Trismus can occur from benign jaw related conditions, often referred to as&#xD;
      temporomandibular disorders (TMD). It can also result from local or metastatic tumor growth&#xD;
      of head and neck (H&amp;N) tumors, and more importantly, as a debilitating side-effect to H&amp;N&#xD;
      oncology treatment, especially radiotherapy&#xD;
&#xD;
      The Gothenburg Trismus Questionnaire (GTQ) is a Patient Reported Outcome, validated in&#xD;
      English, portuguese and sweden language.&#xD;
&#xD;
      The aim of this study is to develop a new tool in french language and to evaluate the&#xD;
      specific impact of trismus on quality of life .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gothenburg Trismus Questionnaire (GTQ)</measure>
    <time_frame>once at inclusion</time_frame>
    <description>patient Reported Outcome measure: score 0-4 (0 means a better outcome, 4 means a worse outcome.)</description>
  </primary_outcome>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Trismus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient treated for trismus&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Inclusion Criteria:&#xD;
&#xD;
               -  Patient treated for trismus&#xD;
&#xD;
               -  Age â‰¥ 18 years old&#xD;
&#xD;
               -  Read, write and understand the French language&#xD;
&#xD;
          -  Exclusion Criteria:&#xD;
&#xD;
               -  Patient under guardianship, deprived of liberty, safeguard of justice&#xD;
&#xD;
               -  Refusal to participate in research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ch Valence</name>
      <address>
        <city>Valence</city>
        <state>Drome</state>
        <zip>26953</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 11, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 16, 2022</last_update_submitted>
  <last_update_submitted_qc>November 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>trismus</keyword>
  <keyword>Patient reported outcomes</keyword>
  <keyword>u Gothenburg Trismus Questionnaire</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trismus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

